Regeneron Pharmaceuticals Inc

15 de set. de 2026, 23:02 UTC

Regeneron Pharmaceuticals Inc. is higher in after-market hours, reflecting broader market strength despite negative economic indicators and rising crude oil inventories.

14 de set. de 2026, 22:06 UTC

Regeneron Pharmaceuticals shares declined in after-market hours following a class action lawsuit alleging securities fraud related to the Phase III Fianlimab-Libtayo Study.

11 de set. de 2026, 20:08 UTC

Regeneron Pharmaceuticals is declining amid two class action lawsuits alleging securities fraud related to its Phase III Fianlimab-Libtayo Study.

10 de set. de 2026, 23:31 UTC

Regeneron Pharmaceuticals shares are trading higher in after-market hours. The stock remains below its 20-day moving average after five consecutive lower daily closes.

9 de set. de 2026, 19:36 UTC

Regeneron Pharmaceuticals is trading lower amid negative sentiment from a securities class action lawsuit regarding misleading statements about its Fianlimab-Libtayo Study.

8 de set. de 2026, 21:21 UTC

Regeneron Pharmaceuticals shares are higher in after-market trading, reflecting positive momentum despite no specific news driving the movement.

4 de set. de 2026, 23:02 UTC

Regeneron Pharmaceuticals shares are trading higher in after-market hours, maintaining strength above its 20-day moving average and near the upper end of its one-month range.

3 de set. de 2026, 23:51 UTC

Regeneron Pharmaceuticals faces a class action lawsuit over misleading statements about its Phase III Fianlimab-Libtayo Study, with shares trading lower in after-market hours.

2 de set. de 2026, 20:01 UTC

Regeneron Pharmaceuticals gains as FDA approves Pasatru for fibrodysplasia ossificans progressiva, enhancing its rare disease portfolio amid ongoing Libtayo recall.

1 de set. de 2026, 20:01 UTC

Regeneron Pharmaceuticals is trading higher today, reflecting strong market activity, with the price above its 20-day moving average and near its one-month range.

31 de ago. de 2026, 20:07 UTC

Regeneron Pharmaceuticals shares are higher, rebounding from earlier lows amid a broader market recovery and rising expectations for an interest rate hike.

28 de ago. de 2026, 20:08 UTC

Regeneron Pharmaceuticals faces a securities fraud lawsuit over misleading statements, contributing to a market cap loss of $11 billion. Shares are lower since Thursday's close.

27 de ago. de 2026, 23:01 UTC

Regeneron Pharmaceuticals shares are trading higher in after-market hours, recovering from an initial dip amid positive labor market data and no specific company news.

26 de ago. de 2026, 23:11 UTC

Regeneron Pharmaceuticals Inc shares are lower in after-market hours, reflecting a decline since Wednesday's close, with no specific news identified for the movement.

25 de ago. de 2026, 19:26 UTC

Regeneron Pharmaceuticals selected Veeva Vault CRM for customer relationship management, enhancing operational efficiencies. Shares are modestly higher since Monday's close.

24 de ago. de 2026, 23:36 UTC

Regeneron Pharmaceuticals shares are slightly higher in after-market hours, reaching a high of 1.09% above Monday's close. No specific news was identified for the move.

21 de ago. de 2026, 23:46 UTC

Regeneron Pharmaceuticals Inc is trading lower in after-market hours, reflecting a slight decline since Friday's close, with no specific news identified.

20 de ago. de 2026, 23:26 UTC

Regeneron Pharmaceuticals Inc shares are higher in after-market trading, maintaining a strong position above the 20-day moving average and near the one-month range.

19 de ago. de 2026, 20:02 UTC

Regeneron Pharmaceuticals gained FDA approval for Pasatru, a treatment for a rare genetic disorder. Shares are advancing, reflecting strong investor sentiment.

13 de ago. de 2026, 19:16 UTC

Regeneron Pharmaceuticals is trading higher as social media highlights REGN17235's potential in ongoing clinical trials, supporting strong performance since Wednesday's close.

12 de ago. de 2026, 23:01 UTC

Regeneron Pharmaceuticals faces a securities fraud lawsuit over misleading statements regarding its Phase III Fianlimab-Libtayo Study, contributing to lower after-market trading.

11 de ago. de 2026, 23:01 UTC

Regeneron Pharmaceuticals shares are modestly higher in after-market hours. No specific company news was identified to explain this movement.

10 de ago. de 2026, 20:02 UTC

Regeneron Pharmaceuticals Inc shares are higher, supported by broader market strength and reduced expectations for Federal Reserve interest rate hikes following Friday's jobs report.

7 de ago. de 2026, 22:16 UTC

Regeneron Pharmaceuticals shares are lower in after-market hours following a class action lawsuit alleging securities fraud and unlawful business practices.

6 de ago. de 2026, 19:26 UTC

Regeneron Pharmaceuticals faces a potential class action lawsuit over alleged securities fraud, contributing to a decline in shares despite receiving Health Canada approval for Libtayo.

5 de ago. de 2026, 20:06 UTC

Regeneron Pharmaceuticals is trading higher, reflecting gains since Tuesday, amid a decline in crude oil prices that eases inflationary pressures.

4 de ago. de 2026, 23:46 UTC

Regeneron Pharmaceuticals is roughly flat in after-market trading, remaining well above its 20-day moving average and near the upper end of its one-month range.

3 de ago. de 2026, 19:46 UTC

Regeneron Pharmaceuticals faces class action lawsuits over alleged securities fraud related to its Phase III Fianlimab-Libtayo Study, contributing to lower share prices.

1 de ago. de 2026, 00:01 UTC

Regeneron Pharmaceuticals shares are lower in after-market hours following a class action lawsuit alleging securities fraud and concerns over a failed clinical trial.

31 de jul. de 2026, 23:06 UTC

Regeneron Pharmaceuticals shares declined in after-market hours following a class action lawsuit alleging securities fraud related to its Phase III study modifications.